Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has determined the shortage of Wegovy® and Ozempic® is resolved. The FDA's assessment confirms the U.S. supply of these ...

The current list price for Ozempic is $997.58 per pen without insurance. While this drug can be expensive, Novo Nordisk offers a savings card for those with commercial or private insurance who are ...

Weight-loss drugs are increasingly popular among employees but weigh heavily on health-insurance budgets. Popular weight-loss drugs such as Ozempic, Wegovy and Zepbound are a growing factor in ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The Partnership for Safe Medicines went so far as to implore Fox not to broadcast the commercial ... FDA-approved semaglutide medicines (Wegovy, Ozempic, and Rybelsus), patient safety remains ...